Living Heart Tissue Research Targets Children's Defects

Families of infants and children with heart defects could eventually see repairs that grow alongside the child.

Updated on Nov. 7, 2026 in Diseases

Translucent glass vessel holding pale living tissue on a steel laboratory bench, with a blurred brick research building visible through a window behind it.
Boston Children's Hospital, Harvard SEAS and NTT Research launched THUMPIN', a partnership backed by up to $29.6 million from ARPA-H to grow heart tissue for children. AI Illustration. Upload story photo >

Live Poll

Should the federal government fund experimental medical research like living heart tissue?

Boston Children's Hospital, Harvard SEAS, NTT Research and Brigham and Women's Hospital announced THUMPIN', a research partnership aiming to build living heart tissue and heart parts for infants and young children with congenital heart disease. The effort is backed by a contract of up to $29.6 million over as many as five years from ARPA-H.

Why it matters

Surgeons can repair many heart defects today, but repairs made in infancy often need to be redone as children grow because materials that stay the same size do not grow with the child. THUMPIN' targets that gap by developing tissue designed to grow and adapt alongside the patient.

This is a program announcement supported by federal contract funding, not a published study with measured outcomes. The figures cited are the maximum contract value and duration, alongside national birth statistics for congenital heart defects.

The players

Boston Children's Hospital

A Boston-based pediatric hospital that leads THUMPIN' and is a major center for the diagnosis and surgical treatment of congenital heart disease.

ARPA-H

The Advanced Research Projects Agency for Health, a federal agency that funds high-risk biomedical research, providing the contract supporting THUMPIN'.

Landmark Bio

A company partnering with THUMPIN' to lead manufacturing of the engineered heart tissue.

The details

Researchers are building heart tissue from living cells designed to grow, function and adapt alongside the child, rather than relying on fixed materials. The work will move from laboratory testing to studies in large animals before any human studies. The team plans to engineer heart valves, blood vessel grafts, patches for heart muscle, parts of the heart's electrical system, single ventricles and, eventually, an entire heart, with manufacturing led in partnership with Landmark Bio.

Timeline

  1. October 21: THUMPIN' partnership announced.

  2. Up to five years: ARPA-H contract period for THUMPIN' funding.

Health Landscape

Current repairs for congenital heart defects can fix many problems in infancy, but the need for repeat procedures as children grow shows the limits of fixed materials. THUMPIN' reflects a shift toward living, growth-capable tissue as a potential alternative to repeated surgical replacement.

Families of children with congenital heart disease may want to ask their cardiologist about how current repairs are expected to change over a child's lifetime. This work is at an early research stage, so it is worth discussing any treatment decisions with your child's doctor rather than waiting on it.

The takeaway

Congenital heart defects are the most common birth defect, and current repairs often need to be redone as children grow. Families affected by these conditions can ask their child's cardiologist about the long-term plan for any repair and what options may come next.

Further reading

For more on the research behind this effort, see Heart Disease coverage.

Source note: This article includes information reported by TechFinancials.

Live Poll

Should the federal government fund experimental medical research like living heart tissue?